NASDAQ:PSNL - Personalis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.25
  • Forecasted Upside: -23.65 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$48.79
▲ +5.18 (11.88%)
1 month | 3 months | 12 months
Get New Personalis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PSNL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSNL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$37.25
▼ -23.65% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Personalis in the last 3 months. The average price target is $37.25, with a high forecast of $50.00 and a low forecast of $24.00. The average price target represents a -23.65% upside from the last price of $48.79.
Buy
The current consensus among 8 contributing investment analysts is to buy stock in Personalis. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/29/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021HC WainwrightBoost Price TargetBuy$30.00 ➝ $50.00Low
i
Rating by S. Ramakanth at HC Wainwright
1/12/2021OppenheimerReiterated RatingHoldHigh
i
1/4/2021Bank of AmericaDowngradeBuy ➝ Neutral$40.00N/A
i
12/16/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$35.00 ➝ $45.00Low
i
12/16/2020Smith Barney CitigroupBoost Price Target$35.00 ➝ $45.00Low
i
11/12/2020Needham & Company LLCBoost Price TargetIn-Line ➝ Buy$25.00 ➝ $32.00Low
i
Rating by Stephen Unger at Needham & Company LLC
11/9/2020Morgan StanleyBoost Price TargetOverweight$25.00 ➝ $27.00High
i
11/6/2020OppenheimerReiterated RatingOutperform ➝ Market PerformHigh
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
10/19/2020Smith Barney CitigroupInitiated CoverageBuy$35.00Medium
i
10/19/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageBuy$35.00Medium
i
10/7/2020BTIG ResearchInitiated CoverageBuy$35.00Medium
i
9/23/2020HC WainwrightReiterated RatingBuy$30.00High
i
Rating by S. Ramakanth at HC Wainwright
8/27/2020HC WainwrightInitiated CoverageBuy$30.00Medium
i
Rating by S. Ramakanth at HC Wainwright
8/17/2020Needham & Company LLCInitiated CoverageBuy$25.00Low
i
8/7/2020Morgan StanleyBoost Price TargetOverweight$14.00 ➝ $25.00Low
i
6/24/2020OppenheimerInitiated CoverageBuy$24.00High
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
5/8/2020Morgan StanleyBoost Price TargetOverweight$13.00 ➝ $14.00High
i
5/7/2020OppenheimerInitiated CoverageBuy$24.00Medium
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
4/21/2020OppenheimerInitiated CoverageBuy$24.00Medium
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
3/26/2020Morgan StanleyLower Price TargetOverweight$16.00 ➝ $13.00Low
i
11/14/2019OppenheimerLower Price TargetOutperform$29.00 ➝ $26.00High
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$22.00High
i
Rating by Derik De Bruin at Bank of America Co.
7/15/2019CIBCInitiated CoverageOutperform ➝ Outperform$29.00Medium
i
7/15/2019CowenInitiated CoverageOutperform ➝ OutperformHigh
i
7/15/2019OppenheimerInitiated CoverageOutperform$29.00 ➝ $29.00High
i
7/15/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$28.00High
i
7/15/2019Bank of AmericaInitiated CoverageNeutral ➝ Neutral$27.00High
i
(Data available from 1/20/2016 forward)
Personalis logo
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has partnership with Berry Genomics. The company was founded in 2011 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $48.79
$44.43
$49.27

50 Day Range

MA: $37.45
$28.17
$44.00

52 Week Range

Now: $48.79
$4.27
$49.27

Volume

1,097,207 shs

Average Volume

1,117,872 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Personalis?

The following Wall Street sell-side analysts have issued reports on Personalis in the last year: Bank of America Co., BTIG Research, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Smith Barney Citigroup, and Zacks Investment Research.

What is the current price target for Personalis?

8 Wall Street analysts have set twelve-month price targets for Personalis in the last year. Their average twelve-month price target is $37.25, suggesting a possible downside of 23.7%. HC Wainwright has the highest price target set, predicting PSNL will reach $50.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $24.00 for Personalis in the next year.

What is the current consensus analyst rating for Personalis?

Personalis currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PSNL will outperform the market and that investors should add to their positions of Personalis.

What other companies compete with Personalis?

How do I contact Personalis' investor relations team?

Personalis' physical mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company's listed phone number is 650-752-1300 and its investor relations email address is investors@personalis.com. The official website for Personalis is www.personalis.com.